m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05168
|
[1] | |||
Non-coding RNA
LINC00662
miR-186-5p
lncRNA miRNA circRNA
Indirect
Enhancement
m6A modification
Linc00662
Linc00662
METTL3
Methylation
: m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | long intergenic non-protein coding RNA 662 (LINC00662) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Long intergenic non-protein coding RNA 662 (LINC00662) | LncRNA | View Details | ||
| Regulated Target | hsa-miR-186-5p | View Details | |||
| Crosstalk Relationship | ncRNA → m6A | Enhancement | |||
| Crosstalk Mechanism | ncRNAs indirectly impacts m6A modification through downstream signaling pathways | ||||
| Crosstalk Summary | METTL3/Long intergenic non-protein coding RNA 662 (LINC00662)/hsa-miR-186-5p feedback loop regulates docetaxel resistance in triple negative breast cancer | ||||
| Responsed Disease | Triple-negative breast cancer | ICD-11: 2C6Z | |||
| Responsed Drug | Docetaxel | ||||
In-vitro Model |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
: m6A sites